Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Intepirdine
Другие языки:

    Intepirdine

    Подписчиков: 0, рейтинг: 0
    Intepirdine
    Intepirdine.svg
    Clinical data
    Other names SB-742457, RVT-101
    Routes of
    administration    		 Oral
    ATC code
    • none
    Legal status
    Legal status
    • Investigational/abandoned
    Identifiers
    • 3-Phenylsulfonyl-8-(piperazin-1-yl)quinoline
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard 100.158.094
    Chemical and physical data
    Formula C19H19N3O2S
    Molar mass 353.44 g·mol−1
    3D model (JSmol)
    • C3CNCCN3c1cccc(c1nc4)cc4S(=O)(=O)c2ccccc2
    • InChI=1S/C19H19N3O2S/c23-25(24,16-6-2-1-3-7-16)17-13-15-5-4-8-18(19(15)21-14-17)22-11-9-20-10-12-22/h1-8,13-14,20H,9-12H2 ☒N
    • Key:JJZFWROHYSMCMU-UHFFFAOYSA-N ☒N
     ☒NcheckY (what is this?)  (verify)

    Intepirdine (INN; developmental codes SB-742457, RVT-101) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects. It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials. GSK chose not to continue development and sold the rights to Axovant Sciences for $5 million in December 2014.

    Results of a phase III clinical trial for the treatment of Alzheimer's disease were reported in September 2017. The trial showed no improvement over control group and Axovant lost 70% of its value upon the announcement of the trial results.

    Intepirdine also entered clinical trials for dementia with Lewy bodies, also with negative results. Consequently, Axovant announced in 2018 that it has discontinued development of this drug.


    Новое сообщение